MSFT 417.14 0.9731% AAPL 229.0 -0.3438% NVDA 119.37 1.5137% GOOGL 163.38 0.989% GOOG 165.11 1.0465% AMZN 178.5 3.7067% META 521.31 0.5963% AVGO 162.82 3.7533% TSLA 214.11 3.7958% TSM 171.7 1.5075% LLY 960.02 2.1081% V 276.37 0.7473% JPM 224.8 1.1656% UNH 590.2 -0.2316% NVO 139.16 1.1926% WMT 77.23 1.0599% LVMUY 149.005 -0.3844% XOM 117.94 -0.1608% LVMHF 745.0 -0.4011% MA 483.34 0.5283%
Last update at 2024-09-05T06:10:00Z
The past three years for Sonic Healthcare (ASX:SHL) investors has not been profitable
Sun 28 Jul 24, 12:26 AMCollins Foods And Two More ASX Dividend Stocks To Consider
Wed 26 Jun 24, 07:05 PMThree ASX Dividend Stocks Offering Yields From 4.1% To 7.0%
Tue 11 Jun 24, 07:07 PMExploring Three ASX Dividend Stocks For Your Investment Portfolio
Tue 28 May 24, 07:06 PMExploring Top ASX Dividend Stocks In May 2024
Mon 13 May 24, 08:06 PMSonic Healthcare Limited's (ASX:SHL) Intrinsic Value Is Potentially 98% Above Its Share Price
Sat 13 Apr 24, 11:04 PMSonic Healthcare Ltd's Dividend Analysis
Fri 01 Mar 24, 10:07 AMBreakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Income before tax | 931.19M | 2077.20M | 1828.59M | 699.06M | 722.26M |
Minority interest | -22.94700M | -54.90000M | 119.36M | 90.64M | 79.54M |
Net income | 684.98M | 1460.57M | 1315.04M | 527.75M | 527.75M |
Selling general administrative | 3868.38M | 3678.97M | 3423.17M | 3225.13M | 3200.03M |
Selling and marketing expenses | 217.02M | 206.13M | 181.71M | 177.25M | 158.56M |
Gross profit | 6889.25M | 7735.69M | 7137.29M | 5714.47M | 5188.77M |
Reconciled depreciation | 702.93M | 675.42M | 641.59M | 605.87M | 273.14M |
Ebit | 1018.21M | 2157.02M | 1921.11M | 811.91M | 808.32M |
Ebitda | 1721.14M | 2832.44M | 2562.71M | 1417.78M | 1081.46M |
Depreciation and amortization | 702.93M | 675.42M | 641.59M | 605.87M | 273.14M |
Non operating income net other | - | - | - | - | - |
Operating income | 1019.10M | 2157.02M | 1921.11M | 811.91M | 808.32M |
Other operating expenses | 3502.33M | 4044.69M | 3822.84M | 3246.32M | 5375.74M |
Interest expense | 87.03M | 79.82M | 92.52M | 112.85M | 86.06M |
Tax provision | 223.26M | 561.74M | 480.94M | 157.16M | 163.19M |
Interest income | 87.03M | 79.82M | 92.52M | 112.85M | 86.06M |
Net interest income | -87.02500M | -79.81900M | -92.51900M | -112.85100M | -79.42700M |
Extraordinary items | - | - | - | - | 0.00000M |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | 223.26M | 561.74M | 480.94M | 157.16M | 163.19M |
Total revenue | 8168.95M | 9340.15M | 8754.12M | 6831.84M | 6184.06M |
Total operating expenses | 5871.04M | 5578.67M | 5216.18M | 4902.56M | 4380.45M |
Cost of revenue | 1279.69M | 1604.46M | 1616.83M | 1117.37M | 995.29M |
Total other income expense net | 10.33M | 17.92M | -1.32900M | 43.31M | -86.06300M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 707.93M | 1515.47M | 1347.66M | 541.90M | 559.07M |
Net income applicable to common shares | 684.98M | 1460.57M | 1315.04M | 527.75M | 549.73M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Total assets | 13014.63M | 12552.01M | 11760.99M | 12127.13M | 9959.83M |
Intangible assets | 7789.62M | 7361.49M | 6712.25M | 6954.90M | 6764.74M |
Earning assets | - | - | - | - | - |
Other current assets | 113.80M | 92.26M | 71.64M | 74.76M | 68.93M |
Total liab | 5092.77M | 5123.84M | 5256.65M | 6462.73M | 4467.97M |
Total stockholder equity | 7736.50M | 7273.14M | 6384.99M | 5573.75M | 5412.33M |
Deferred long term liab | - | - | - | - | - |
Other current liab | 8.23M | 21.37M | 82.45M | 18.19M | 48.29M |
Common stock | 3842.42M | 3860.95M | 4081.98M | 4000.91M | 3966.89M |
Capital stock | 3842.42M | 3860.95M | 4081.98M | 4000.91M | 3966.89M |
Retained earnings | 3554.20M | 3351.02M | 2322.16M | 1397.42M | 1299.16M |
Other liab | 460.74M | 368.69M | 355.33M | 439.84M | 408.99M |
Good will | 7237.43M | 6852.96M | 6231.85M | 6486.33M | 6320.73M |
Other assets | 80.19M | 259.75M | 103.13M | 127.29M | 85.46M |
Cash | 797.99M | 780.00M | 899.83M | 1230.15M | 736.65M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 1878.34M | 2084.27M | 2217.94M | 2070.13M | 1849.38M |
Current deferred revenue | 563.33M | 702.50M | 557.52M | 404.99M | 347.78M |
Net debt | 2302.49M | 2232.74M | 2334.98M | 3385.73M | 2298.95M |
Short term debt | 346.79M | 341.86M | 551.43M | 663.12M | 826.00M |
Short long term debt | - | - | 228.94M | 364.20M | 824.88M |
Short long term debt total | 3100.48M | 3012.74M | 3234.81M | 4615.88M | 3035.60M |
Other stockholder equity | -7396.62000M | -7217.87000M | -6404.28400M | -5398.47400M | 146.28M |
Property plant equipment | 2798.11M | 2624.86M | 2552.92M | 2498.08M | 1268.32M |
Total current assets | 2133.17M | 2305.91M | 2284.57M | 2455.11M | 1753.18M |
Long term investments | 175.80M | 145.22M | 108.11M | 91.75M | 88.14M |
Net tangible assets | -53.11500M | -88.34600M | -327.26500M | -1381.15100M | -1352.40800M |
Short term investments | - | - | - | - | - |
Net receivables | 1022.17M | 1217.46M | 1088.72M | 986.77M | 827.93M |
Long term debt | 1673.46M | 1576.93M | 1592.38M | 2872.43M | 2207.88M |
Inventory | 199.20M | 216.19M | 224.39M | 163.43M | 119.67M |
Accounts payable | 959.99M | 1018.55M | 1026.54M | 983.83M | 627.31M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 339.88M | 61.17M | -19.15800M | 175.43M | 146.28M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | 4000.91M | 3966.89M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | -0.14000M | -0.14700M | -0.20900M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 45.56M | 45.54M | 37.86M | 56.53M | 46.29M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 10881.46M | 10246.10M | 9476.42M | 9672.02M | 8206.65M |
Capital lease obligations | 1427.02M | 1435.80M | 1413.49M | 1379.25M | 2.83M |
Long term debt total | 2753.69M | 2670.88M | 2683.38M | 3952.76M | 2209.59M |
Breakdown | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 | 2019-06-30 |
Investments | -580.04100M | -81.20900M | -20.92100M | -334.91700M | -1099.32900M |
Change to liabilities | -75.54500M | 17.29M | 96.42M | 343.15M | 29.04M |
Total cashflows from investing activities | -580.04100M | -989.18000M | -386.75000M | -334.91700M | -1099.32900M |
Net borrowings | -374.31300M | -624.69200M | -1582.05900M | -147.40300M | 117.41M |
Total cash from financing activities | -911.51100M | -1349.29400M | -1954.65800M | -536.73600M | 687.67M |
Change to operating activities | 9.74M | -41.81100M | 56.65M | 40.07M | 7.95M |
Net income | 684.98M | 1460.57M | 1315.04M | 527.75M | 549.73M |
Change in cash | 18.00M | -119.83000M | -330.32200M | 493.50M | 423.38M |
Begin period cash flow | 780.00M | 899.83M | 1230.15M | 736.65M | 313.27M |
End period cash flow | 797.99M | 780.00M | 899.83M | 1230.15M | 736.65M |
Total cash from operating activities | 1471.03M | 2225.82M | 2042.84M | 1360.30M | 847.31M |
Issuance of capital stock | 84.27M | 48.81M | 53.63M | 23.00M | 943.98M |
Depreciation | 632.83M | 675.42M | 641.59M | 605.87M | 273.14M |
Other cashflows from investing activities | -83.02800M | -610.59100M | 24.40M | -1.82500M | -712.68100M |
Dividends paid | -490.53000M | 470.87M | 426.23M | 412.33M | 373.72M |
Change to inventory | 27.46M | 9.88M | -65.53500M | -42.84600M | -12.87800M |
Change to account receivables | 244.26M | -83.01700M | -146.64400M | -138.49800M | 12.19M |
Sale purchase of stock | -130.93300M | -302.54800M | 53.63M | 23.00M | 943.98M |
Other cashflows from financing activities | -255.09500M | -206.65300M | -205.45200M | 1168.11M | 1363.84M |
Change to netincome | 42.41M | 2225.82M | 34.02M | 5.41M | -32.46500M |
Capital expenditures | 497.01M | 378.59M | 363.19M | 333.09M | 386.65M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 271.72M | 1.99M | 2.92M | 5.95M | 6.64M |
Stock based compensation | 18.45M | 17.24M | 12.64M | 6.33M | - |
Other non cash items | 153.22M | -2135.98300M | -1956.63400M | -1133.61700M | -822.86900M |
Free cash flow | 974.02M | 1847.23M | 1679.64M | 1027.21M | 460.66M |
Sector: Healthcare Industry: Diagnostics & Research
Company | Change (AUD) | Price (AUD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
SHL Sonic Healthcare Ltd |
0.23 0.85% | 27.14 | 24.93 | 17.92 | 1.55 | 1.69 | 1.96 | 10.59 |
HLS Healius Ltd |
-0.06 3.42% | 1.70 | - | 21.10 | 0.52 | 0.84 | 1.43 | -3.5527 |
IDX Integral Diagnostics Ltd |
-0.03 1.15% | 2.58 | - | 19.12 | 1.22 | 1.85 | 1.97 | 71.46 |
MVF Monash IVF Group Ltd |
-0.025 2.14% | 1.15 | 22.00 | - | 2.40 | 2.05 | 2.89 | 13.15 |
ACL Australian Clinical Labs Ltd |
-0.09 2.71% | 3.23 | 30.00 | 13.35 | 0.75 | 3.09 | 1.22 | 5.27 |
Sonic Healthcare Limited offers medical diagnostic services to medical practitioners, hospitals, community health services, and their collective patients. The company provides laboratory medicine/pathology testing services, such as biochemistry, cytopathology, genetics, haematology, histopathology, immunoserology, microbiology, molecular pathology, prenatal testing, toxicology, and ancillary functions; and radiology services, including magnetic resonance imaging, computed tomography (CT), ultrasound, X-ray, mammography, nuclear medicine, PET CT, interventional procedures, and bone mineral densitometry. It offers primary care medical services comprising general practice clinics, occupational health services, skin cancer clinics, after-hours general practice services, general practice IT solutions, and community-based healthcare services. The company operates in Australia, the United Kingdom, Ireland, the United States, Germany, Switzerland, New Zealand, Belgium, and internationally. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.
Grosvenor Place, Sydney, NSW, Australia, 2000
Name | Title | Year Born |
---|---|---|
Dr. Colin Stephen Goldschmidt F.A.I.C.D., F.R.C.P.A., M.B.B.Ch. | CEO, MD & Exec. Director | 1954 |
Mr. Christopher David Wilks B.Com., F.A.C.I.D., F.A.I.C.D. | Fin. Director, CFO & Exec. Director | 1958 |
Mr. Peter Savage | Chief Bus. Officer | NA |
Dr. Stephen Fairy | Global Chief Medical Officer | NA |
Mr. David Byrne | Chief Exec. Officer of The Doctors Laboratory | 1959 |
Mr. Paul J. Alexander B.Ec., C.A., F.Fin | Deputy CFO & Company Sec. | 1966 |
Mrs. G. Schottdorf | Chief Exec. Officer of Schottdorf Group | NA |
Dr. Julian Adler | Chief Exec. Officer of Sonic Imaging | NA |
Prashan Kulasekera | Assistant Company Sec. | 1972 |
Mr. David Byrne | Chief Executive Officer of The Doctors Laboratory | 1959 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.